Private Advisor Group LLC Has $62.40 Million Position in Eli Lilly and Company (NYSE:LLY)

Private Advisor Group LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 80,829 shares of the company’s stock after selling 467 shares during the period. Private Advisor Group LLC’s holdings in Eli Lilly and Company were worth $62,399,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Inscription Capital LLC boosted its position in Eli Lilly and Company by 1.0% during the third quarter. Inscription Capital LLC now owns 1,222 shares of the company’s stock valued at $1,083,000 after buying an additional 12 shares during the period. Garner Asset Management Corp boosted its holdings in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock valued at $411,000 after acquiring an additional 12 shares during the period. Detalus Advisors LLC grew its position in Eli Lilly and Company by 1.7% during the 3rd quarter. Detalus Advisors LLC now owns 798 shares of the company’s stock worth $707,000 after acquiring an additional 13 shares during the last quarter. PSI Advisors LLC increased its stake in Eli Lilly and Company by 0.4% in the 3rd quarter. PSI Advisors LLC now owns 2,908 shares of the company’s stock worth $2,576,000 after purchasing an additional 13 shares during the period. Finally, Boston Financial Mangement LLC lifted its position in Eli Lilly and Company by 0.3% in the third quarter. Boston Financial Mangement LLC now owns 5,020 shares of the company’s stock valued at $4,447,000 after purchasing an additional 13 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on LLY shares. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Wells Fargo & Company decreased their price objective on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Bank of America reiterated a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Barclays lowered their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Finally, StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Trading Up 1.1 %

NYSE:LLY opened at $866.69 on Thursday. The firm has a market capitalization of $822.77 billion, a P/E ratio of 74.01, a PEG ratio of 1.35 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company’s 50-day simple moving average is $797.80 and its 200 day simple moving average is $845.87.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback plan on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 51.24%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.